NO20042565L - Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav - Google Patents

Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav

Info

Publication number: NO20042565L
Authority: NO; Norway
Prior art keywords: methods; ostradiol; beta; administration; preparation
Prior art date: 2001-12-21

Application number

NO20042565A

Other languages

English (en)

Inventor

Oluwole T Aloba

Tina M De Vries

Original Assignee

Galen Chemicals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-21

Filing date

2004-06-18

Publication date

2004-06-18

2004-06-18 Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd

2004-06-18 Publication of NO20042565L publication Critical patent/NO20042565L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Urology & Nephrology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20042565A 2001-12-21 2004-06-18 Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav NO20042565L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10/023,748 US6962908B2 (en)	2001-12-21	2001-12-21	Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation
PCT/US2002/040728 WO2003055495A1 (en)	2001-12-21	2002-12-20	ORAL PHARMACEUTICAL PRODUCTS CONTAINING 17β-ESTRADIOL-3-LOWER ALKANOATE, METHOD OF ADMINISTERING THE SAME AND PROCESS OF PREPARATION

Publications (1)

Publication Number	Publication Date
NO20042565L true NO20042565L (no)	2004-06-18

Family

ID=21816969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042565A NO20042565L (no)	2001-12-21	2004-06-18	Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav

Country Status (11)

Country	Link
US (3)	US6962908B2 (no)
EP (1)	EP1461043A1 (no)
JP (1)	JP2005517673A (no)
CN (1)	CN1273141C (no)
AU (1)	AU2002359758A1 (no)
CA (1)	CA2470703C (no)
IL (2)	IL160797A0 (no)
MX (1)	MXPA04006057A (no)
NO (1)	NO20042565L (no)
NZ (1)	NZ532491A (no)
WO (1)	WO2003055495A1 (no)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
FR2857591B1 (fr) *	2003-07-17	2007-11-02	Ethypharm Sa	Particules comprenant un principe actif sous forme de co-precipite
EP2409690B1 (en) *	2003-09-29	2022-11-09	Novo Nordisk Health Care AG	Improved stability of progestogen formulations
EP1670440B1 (en) *	2003-09-29	2014-04-30	Novo Nordisk Femcare AG	Hrt formulations
ATE526988T1 (de) *	2003-10-08	2011-10-15	Mallinckrodt Llc	Methylphenidat-lösung und relevante verabreichungs- und herstellungsverfahren
GT200500315A (es) *	2004-11-02	2006-06-06		Formas de dosificacion oral solidas que contienen una dosis baja de estradiol
US8022053B2 (en) *	2004-11-02	2011-09-20	Bayer Schering Pharma Aktiengesellschaft	Oral solid dosage forms containing a low dose of estradiol
DE602006013114D1 (de) *	2005-04-28	2010-05-06	Wyeth Corp	Mikronisiertes tanaproget und zusammensetzungen damit
ATE460937T1 (de) *	2005-04-28	2010-04-15	Wyeth Corp	Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
CA2674776A1 (en) *	2006-12-20	2008-07-03	Duramed Pharmaceuticals, Inc.	Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
US20100022494A1 (en) *	2008-07-24	2010-01-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022487A1 (en) *	2008-07-24	2010-01-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100061976A1 (en) *	2008-07-24	2010-03-11	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
US20110190201A1 (en) *	2008-07-24	2011-08-04	Searete Llc	Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
US20100022497A1 (en) *	2008-07-24	2010-01-28	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
ES2885523T3 (es)	2011-11-23	2021-12-14	Therapeuticsmd Inc	Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
CA3020153A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
CN114573654B (zh) *	2020-12-01	2025-09-12	北京奇明达企业管理有限公司	17-O-乙酰-17-β雌二醇的自组装的三聚体、其制备、活性和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE699310C (de) *	1936-11-20	1940-11-27	Chemische Ind Ges	Verfahren zur Herstellung von in 3-Stellung veresterten Verbindungen vom Typus des Oestradiols
US3568828A (en)	1967-03-01	1971-03-09	Squibb & Sons Inc	Modified sequential oral contraceptive
US3478070A (en) *	1967-12-26	1969-11-11	American Home Prod	Process for selectively acylating the 3-ol group in polyhydroxy 13-alkyl gona-(and 8 - isogona) - 1,3,5 - (10) - trienes and delta - 7 -,delta - 8(9),delta - 9(11) -,and delta - 8(9),14(15) - dehydro derivatives thereof
US4544554A (en)	1983-09-26	1985-10-01	Ortho Pharmaceutical Corporation	Triphasic oral contraceptive
IE67345B1 (en)	1991-03-12	1996-03-20	Akzo Nv	Low dose dry pharmaceutical preparations
US5928668A (en)	1993-12-21	1999-07-27	Applied Analytical Industries, Inc.	Method for dry blend compression of medicaments
US5976570A (en)	1993-12-21	1999-11-02	Applied Analytical Industries, Inc.	Method for preparing low dose pharmaceutical products
DE4344462C2 (de)	1993-12-22	1996-02-01	Schering Ag	Zusammensetzung für die Empfängnisverhütung
IL116433A (en)	1994-12-19	2002-02-10	Galen Chemicals Ltd	INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS
US6117446A (en)	1999-01-26	2000-09-12	Place; Virgil A.	Drug dosage unit for buccal administration of steroidal active agents

2001
- 2001-12-21 US US10/023,748 patent/US6962908B2/en not_active Expired - Lifetime
2002
- 2002-12-20 CA CA2470703A patent/CA2470703C/en not_active Expired - Lifetime
- 2002-12-20 IL IL16079702A patent/IL160797A0/xx unknown
- 2002-12-20 WO PCT/US2002/040728 patent/WO2003055495A1/en not_active Ceased
- 2002-12-20 EP EP02794318A patent/EP1461043A1/en not_active Withdrawn
- 2002-12-20 CN CNB028198506A patent/CN1273141C/zh not_active Expired - Lifetime
- 2002-12-20 NZ NZ532491A patent/NZ532491A/en not_active IP Right Cessation
- 2002-12-20 JP JP2003556072A patent/JP2005517673A/ja active Pending
- 2002-12-20 AU AU2002359758A patent/AU2002359758A1/en not_active Abandoned
- 2002-12-20 MX MXPA04006057A patent/MXPA04006057A/es active IP Right Grant
2004
- 2004-03-09 IL IL160797A patent/IL160797A/en active IP Right Grant
- 2004-04-29 US US10/833,997 patent/US7572779B2/en not_active Expired - Lifetime
- 2004-06-18 NO NO20042565A patent/NO20042565L/no not_active Application Discontinuation
2005
- 2005-06-17 US US11/154,704 patent/US7799771B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
IL160797A (en)	2013-11-28
US7799771B2 (en)	2010-09-21
IL160797A0 (en)	2004-08-31
US20050234028A1 (en)	2005-10-20
US20030118638A1 (en)	2003-06-26
CA2470703A1 (en)	2003-07-10
AU2002359758A1 (en)	2003-07-15
US6962908B2 (en)	2005-11-08
NZ532491A (en)	2005-05-27
MXPA04006057A (es)	2005-04-19
US7572779B2 (en)	2009-08-11
CN1564689A (zh)	2005-01-12
CN1273141C (zh)	2006-09-06
WO2003055495A1 (en)	2003-07-10
EP1461043A1 (en)	2004-09-29
US20040209856A1 (en)	2004-10-21
JP2005517673A (ja)	2005-06-16
CA2470703C (en)	2011-03-15

Publication	Publication Date	Title
NO20042565L (no)	2004-06-18	Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav
LTC1345910I2 (lt)	2022-06-10	Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
AU2002357012A1 (en)	2003-06-10	Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
NO20022998L (no)	2002-08-15	Farmasöytiske preparater som tilveiebringer foröket konsentrasjon av medikament
NO20016277D0 (no)	2001-12-20	Systemer og fremgangsmåter for aerolisering av farmasöytiske formuleringer
NO20034079L (no)	2003-11-17	Fremgangsmåte for fremstilling av interpolymerer og produkter laget derav
NO996433L (no)	2000-02-14	Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
NO20010277L (no)	2001-03-15	Benzocykloheptener, fremgangsmÕte for fremstilling derav, farmasøytiske preparater inneholdende disse, og deres anvendelse for fremstilling av medikamenter
ATE317260T1 (de)	2006-02-15	Pharmazeutische formulierungen mit platinderivaten
NO20040268L (no)	2004-03-23	Nye 2H-pyridazin-3-derivater, farmasoytiske preparater inneholdende slike og fremgangsmate for fremstilling av den aktive ingrediensen
NO984878D0 (no)	1998-10-19	Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
NO20026212D0 (no)	2002-12-23	Forbindelse for medikamentavleveringssystem og fremgangsmåte for fremstilling av forbindelsen
NO20015659L (no)	2002-01-18	Purinderivater, fremstillingsmetode og farmasöytiske preparater inneholdende disse
NO20001717D0 (no)	2000-04-03	Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
EE200300135A (et)	2003-08-15	Trüptamiini derivaadid ja analoogsed ühendid ningneid sisaldavad farmatseutilised preparaadid
ATE254124T1 (de)	2003-11-15	Octahydro-2h-pyrido(1,2-a)pyrazinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
NO20043007L (no)	2004-07-15	Farmasoytisk suspensjon for oral administrering
NO20023249D0 (no)	2002-07-04	Nye substituerte pyrazolo(4,3-e)ediazepiner, farmasöytiske preparater inneholdende disse, anvendelse som medisinske produkterog fremgangsmåter for fremstilling derav
NO20013141D0 (no)	2001-06-22	Arylalkanoylderivater, fremgangsmåte for fremstilling derav, deres anvendelse og farmasöytiske produkter inneholdende disse
IL160886A0 (en)	2004-08-31	Nicotine containing pharmaceutical formulations and use thereof
AU2002317063A (en)	2002-12-23	Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
NO20020777L (no)	2002-02-15	Farmasöytiske preparater inneholdende derivater og fremgangsmåte for fremstilling derav
PL369632A1 (en)	2005-05-02	Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
AU2002317063A1 (en)	2002-12-23	Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
NO20042022L (no)	2004-05-14	Fast legemiddelformulering som inneholder pipiperazinurea-derivat og fremgangsmate for fremstilling av formuleringen

Legal Events

Date	Code	Title	Description
2005-09-12	FC2A	Withdrawal, rejection or dismissal of laid open patent application